To clarify the exact mechanisms of the pharmacological effects of glucagon on gastro intestinal motility, the following experiments were performed on the conscious and anesthe tized dogs. 1) During phase I of interdigestive migrating contractions (IMC) , glucagon (5 infusion for 5 minutes) induced phasic contractions in the duodenum , jejunum and ileum, but not in the antrum. These excitatory responses were also observed in the truncal vagotomized dogs. These contractions were abolished by atropine or hex amethonium in the conscious dogs, and also by tetrodotoxin in the anesthetized dogs . 2) Glucagon inhibited cisapride-induced contractions only in the antrum in the conscious dogs .
Introduction
Glucagon is one of the peptide hormones secreted from the A cells of the pancreatic islets.
It antagonizes the effects of insulin and plays an important role in the regulation of the blood glucose. It has also a number of other actions, including a hypomotility and hypotonicity action on gastrointestinal motility (Stunkard et al., 1955; Sudsaneh et al., 1959; Detevall et al., 1963; Necheles et al., 1966) . It is thus now commonly used as a pre-treatment drug for radiodiagnostics (Miller et al., 1974; Kreel et al., 1975; Carsen et al., 1976; Ishii et al., 1978) or endoscopic examinations (Qvigstad et al., 1979) of gastrointestinal tract in patients with complications such as heart diseases (Giesen, 1978; Harada et al., 1997) , glaucoma (Sissons et al., 1991; Fink et al., 1995) and hypertrophy of the prostate (Chernish et al., 1972) . The enteric nervous system may be a target of glucagon (Takenaka et al., 1975; Lin et al., 1989) , but the exact mechanisms of the inhibitory effects have not been elucidated.
On the other hand, the gene encoding proglucagon, the precursor of glucagon, is expressed not only in the pancreatic islets but also in the endocrine cells of the gastrointestinal mucosa.
The proglucagon-derived peptides produced by the L cells in the jejunum, ileum and colon are called enteroglucagon and are partly composed of pancreatic glucagon. It is secreted into the blood in response to ingestion of carbohydrates and long-chain fatty acids, and may be one of the candidates of the "ileal-brake", which inhibits upper gastrointestinal functions elicited by the presence of unabsorbed nutrients in the ileum (Holst, 1997) .
Glucagon and enteroglucagon interact with a common receptor in vitro (Gros, et al., 1993) , but its physiological role in vivo is not yet clear.
The purpose of the present study was to investigate the pharmacological effects of glucagon and the exact mechanisms of its action on interdigestive contractions of the gastro intestinal tract in the conscious and anesthetized dogs.
Materials and methods

Preparation of animals
Eleven healthy adult mongrel dogs of either sex weighing 8.8-17.5 kg were used in these experiments. The procedures were approved by the Review Committee on Laboratory Animal
Science of Hiroshima University, Japan. Under pentobarbital sodium anesthesia (25mg/kg body weight, i.v.), the abdominal cavity was opened and strain gauge force transducers (Star Medical, Japan, F-12IS) were sutured onto the serosal side of various regions of the gastrointe stinal tract (the gastric antrum 5cm proximal to the pyloric ring, the duodenum at the level of the main pancreatic duct, the jejunum 15cm distal to the ligament of Treitz, and the ileum 15 cm proximal to the ileo-cecal junction) so that the contractile activities of the circular muscle could be recorded. A truncal vagotomy was performed on two of the dogs at the level of the abdominal esophagus. The completeness of the truncal vagotomy was examined according to a previous report (Mukai, 1984) . Transducer lead wires were taken out of the abdominal cavity through the subcutaneous tunnel and brought out through a skin incision at the middle 147 region of the superior end of the bilateral shoulder blade . After closure of the abdominal cavity, Silastic tubes (Argyle, Japan, 1216-27-P) were inserted into the right and left femoral vein for intravenous administration of agents or blood sampling. The tubes were brought out through another skin incision on the back and their outer ends were fixed to the skin with nylon sutures. After surgery, jacket-type protectors (Star Medical, Japan , FPJ-12) were put on the dogs to protect the lead wires and the tubes from scratching and biting . The dogs were housed and a dministered intravenously 200ml of physiologi cal saline with 0.5g of cefminox sodium (CMNX) for 3 days after the operation. Pelleted dog diet (150g, Nihon Clea, Japan, CD-5) was mixed with bread gruel (bread 500g boiled with 200 ml of water, and 25g of powdered skim milk added), and given regularly at noon (approximate ly 600 kcal/day).
Monitoring of gastrointestinal contractions
The lead wires of the strain gauge force transducers were connected to an amplifier (Star Medical, Japan, FS-02) and a recorder (Graphtec, Japan, and also recorded. The motility index was calculated as in a previous report (Okajima , 1988 These glucagon-induced excitatory responses were completely blocked by atropine sulfate (0.1mg/kg body weight, i.v.) ( Fig. 1-B ) or hexamethonium bromide (10mg/kg body weight, bolus injection and 10mg/kg body weight, drip infusion for 30minutes) ( C: Glucagon-induced contractions were also completely inhibited by hexamethonium bromide (C6).
pride-induced contractions with or without pre-treatment with hexamethonium bromide (p< 0.001 and p<0.01, respectively), whereas in the duodenum glucagon inhibited these contractions only after pre-treatment with hexamethonium bromide (p<0.01).
On the other hand, in the anesthetized dogs after pre-treatment with tetrodotoxin, glucagon did not affect exogenous acetylcholine, acetylcholine chloride (0.5mg/kg body weight, drip infusion for 10 minutes)-induced contractions in any region (Fig. 6 ). Fig. 8-A) . As shown in Fig. 8 -B, glucagon inhibited these contractions only in the antrum. These glucagon-induced inhibitory responses were observed at doses of 5, 10, 20, kg or more. Furthermore, pre-treatment with hexamethonium bromide partially inhibited and modified erythromycin lactobionate-induced contractions ( Fig. 8-C) . After blocking the preganglionic excitatory responses of glucagon with hexamethonium bromide, glucagon com pletely inhibited these contractions in the duodenum, jejunum and ileum as well as in the antrum (Fig. 8-D) . These results are shown in Fig. 9 by means of a motility index-15 (MI-15). In the antrum and duodenum, hexamethonium bromide partially inhibited erythromycin lactobionate In the other regions spontaneous contractions were not affected .
4. Influences of glucagon on gastrointestinal motility through hyperglycemia or hyperinsulinemia minutes), the blood glucose concentration was measured. The maximal glucose concentration , approximately 180mg/dl, was observed 5 minutes after the administration of glucagon. The maximal glucose concentration was compatible with that of an administration of glucose at a dose of 0.3g/kg (Fig. 10) . In order to examine the indirect effects of glucagon on gastrointesti nal motility through hyperglycemia, glucose was used in place of glucagon. On phase I contractile activities administration of glucose (0.3g/kg body weight, i.v.) did not induce contractions in any region (Fig. 11-A) . Moreover, glucose did not affect either the cisaprideinduced contractions (Fig. 11-B) or erythromycin lactobionate-induced contractions ( Fig. 11-C) in any region. On the other hand, insulin was released in response to glucagon-induced hyperglycemia.
As insulin-induced contractions were via the central nervous system , in the truncal vagotomized dogs insulin-induced contractions could not be observed in any region , but glucagon-induced excitatory responses were induced even in the truncal vagotomized dogs in my experiments (Fig. 2) . (EM : erythromycin lactobionate, C6 : hexamethonium bromide)
Discussion
One of the important actions of glucagon is a hypomotility and hypotonicity action on gastrointestinal motility (Necheles et al., 1966) . Zollinger and Ellison (1955) were the first to recognize the effects of glucagon on the gastrointestinal tract. It reduced gastric hunger contractions in 7 healthy volunteers (Stunkard et al., 1955) and promptly inhibited motor activities of the stomach and duodenum (1mg/body, i.m.) for 25 minutes in humans (Nishioka in the duodenum in dogs (Furukawa, 1987) , and a low dose continuous administration activated B : Glucagon strongly inhibited erythromycin lactobionate-induced contractions only in the antrum, but scarcely had any influence in the duodenum, jejunum and ileum. duodenal motility while a high dose bolus injection inhibited it in dogs (Wingate et al., 1979 ).
As seen above, in previous papers the effects of glucagon on gastrointestinal motility were inconsistent in various regions and various species. The mechanisms of its inhibitory effects were focused on in some previous experiments. They were not concerned with direct effects on the receptors on smooth muscle, but on the myenteric nervous system in rabbits (Takenaka et al., 1975) , or the interference of intramural cholinergic neuronal transmission in rat esophagus (Lin et al., 1989) . Until now it has been thought that the enteric nervous system might be a target of glucagon. On the other hand, some papers have indicated that glucagon acts directly on gastric smooth muscle cells in humans (Wingate et al., 1979; VandeCreek et al., 1986) . In my experiments the exact mechanisms of glucagon on upper gastrointestinal motility were examined in the conscious or anesthetized dogs.
Intravenous administration of glucagon during the quiescent phase of IMC induced a series of strong contractions in the duodenum, jejunum and ileum in the conscious dogs. However, no contractions were induced in the antrum (Fig. 1-A) . These contractions were also induced in the truncal vagotomized dogs in a fasted state (Fig. 2) . The glucagon-induced contractions were inhibited by atropine sulfate or hexamethonium bromide ( Fig. 1-B and C) . Moreover, after pre-treatment with tetrodotoxin in the anesthetized dogs, glucagon did not induce contractions in any region (Fig. 3) . These facts indicate that glucagon-induced excitatory responses in the duodenum, jejunum and ileum may be mediated by preganglionic cholinergic neurons involving nicotinic and muscarinic receptors in the myenteric plexus.
In previous reports it was not clear how glucagon affected antral motility during the quiescent phase of IMC. To clarify whether glucagon inhibited antral motility or not, I investigated the effects of glucagon on contractions induced by cisapride, which is known to be an agonist at neural 5-hydroxytryptamine (5-HT) 4 receptors in the cholinergic motor path- ways and accelerates endogenous acetylcholine release from cholinergic nerve endings in the myenteric plexus (Hardcastle et al., 1984 ; Suzuki et al., 1985 ; Fujii et al., 1988 ; Taniyama et al., 1991) . Cisapride induced strong rhythmical contractions in every region (Fig . 4-A) , and glucagon inhibited cisapride-induced contractions only in the antrum (Fig. 4-B) . Furthermore, after administration of hexamethonium bromide to prevent the preganglionic excitatory responses of glucagon, glucagon completely inhibited cisapride-induced contractions in the duodenum, jejunum and ileum as well as in the antrum (Fig. 4-D) . On the other hand, glucagon did not inhibit exogenous acetylcholine-induced contractions in any region after pre-treatment with tetrodotoxin in the anesthetized dogs (Fig. 6 ). These facts indicate that glucagon latently inhibits cholinergic motor activities not directly via either receptor on the smooth muscle cells but through postganglionic neurons in the duodenum, jejunum and ileum as well as in the antrum, whereas glucagon also preganglionically activates cholinergic activity in the duode num, jejunum and ileum. As a result, cisapride-induced contractions were inhibited by glucagon only in the antrum, and were not inhibited in the duodenum, jejunum and ileum in a conscious state (Fig. 4-B) .
How glucagon affects phase III contractions is not yet clear. In my experiments glucagon instantly eliminated phase III contractions in the antrum and somewhat altered the patterns of phase III contractions in the duodenum, jejunum and ileum (Fig. 7-A and B) . These findings in the antrum and duodenum are consistent with previous reports in dogs (Wingate et al., 1979 ; Furukawa, 1987) . To clarify these mechanisms, erythromycin lactobionate was used to induce phase III-like contractions (Itoh et al., 1984 ; Satoh et al., 1994) . Administration of eryth romycin lactobionate during phase I of IMC immediately induced strong rhythmical contrac tions similar to spontaneous phase III contractions (Fig. 8-A) . It has been commonly accepted that the cholinergic pathways and 5-HT3 neurons are involved in these contractions. (Itoh et al., 1977 ; Itoh et al., 1978 ; Itoh et al., 1991 ; Mizumoto et al., 1993 ; Haga et al., 1996) . In fact, these contractions were completely inhibited by atropine sulfate and partially inhibited by hexamethonium bromide (Qin et al., 1993 ; Shiba et al., 1995) . Glucagon inhibited eryth romycin lactobionate-induced contractions only in the antrum (Fig. 8-B) , whereas in the duodenum, jejunum and ileum they were strongly inhibited by glucagon only after pre-treatment with hexamethonium bromide (Fig. 8-C and D).
As stated above, it is suspected that glucagon latently postganglionically inhibits phase III contractions or erythromycin lactobionate-induced phase III-like contractions in any region, but in the duodenum, jejunum and ileum reverse effects through preganglionic cholinergic neurons are so strong that intestinal motility is not quite affected in a conscious state (Fig. 7- B and 8-B). These paradoxical effects of glucagon between antral and intestinal phase III contractions are similar to the antagonism of neural 5-HT3 receptors (Itoh et al., 1991) . These facts indicate the involvement of cholinergic neurons and possibly 5-HT3 receptors or neurons in terms of the inhibitory effects of glucagon.
Finally, to confirm that these excitatory or inhibitory effects were not an indirect action of glucagon through hyperglycemia or hyperinsulinemia, some additional experiments were performed. It is well known that continuous hyperglycemia inhibits gastrointestinal motility in a conscious state. Gastric contractions were nearly absent at a serum glucose level of 250 mg/kg for 3 hours and markedly reduced at 175 and 140 mg/dl, but duodenal phase III activities were unchanged at all levels of glucose infusion in healthy volunteers (Barnett et al., 1988) .
However, in my experiments hyperglycemia followed by glucagon administration continued for a short period (Fig. 10) , so even when glucose was administered in place of glucagon, no excitatory or inhibitory responses were observed in any region (Fig. 11-A , B and C). On the other hand, it was also reported that hyperinsulinemia enhanced cholinergic motor activities via the central nervous system (Rayner et al., 1981) and increased antral motility in the vagal innervated dogs but did not increase it in the truncal vagotomized dogs (Yokomichi et al., 1976) .
In my experiments, glucagon-induced excitatory responses were induced even in the truncal vagotomized dogs (Fig. 2) . These facts indicate that these excitatory and inhibitory effects are not an indirect action through secondary hyperglycemia or hyperinsulinemia , but a direct pharmacological action of glucagon itself in the myenteric plexus. In previous studies it was not clear whether glucagon acted directly on glucagon receptors or other receptors located on the neurons, or acted indirectly through other chemical mediators .
Many hormones, including enteroglucagon, might act through paracrine release of somatostatin (Lloyd, 1994) . In fact, glucagon receptors were detected in a somatostatin-secreting cell line RIN T3 (Gros et al., 1993) . Furthermore, glucagon receptor mRNA transcripts were detected in the central nervous system, jejunum and ileum in both fetal and adult mice (Campos et al ., 1994) , but what kind of neurons glucagon receptors were located on was not ascertained .
Further examination will clarify the location of glucagon receptors .
In conclusion, glucagon inhibits cholinergic motor activities not directly by binding to either receptor on the smooth muscle cells but through postganglionic cholinergic neurons, and possibly 5-HT neurons, in the duodenum, jejunum and ileum as well as in the antrum.
On the other hand, glucagon activates cholinergic motor activities through preganglionic cholinergic neurons involving nicotinic and muscarinic receptors in the duodenum , jejunum and ileum.
Eventually, in a conscious state, glucagon inhibits only antral contractions.
